Caris Life Sciences

245 articles with Caris Life Sciences

• Caris Life Sciences to Showcase Extensive Research with Leading Cancer Centers Reflecting Its Commitment to Improving Outcomes for Patients at ASCO 2022

  5/26/2022

  Caris Life Sciences® announced that the company and partners within its Precision Oncology Alliance™ will collectively present 45 studies across more than 20 various solid tumor types at the 2022 American Society of Clinical Oncology Annual Meeting from June 3-7, 2022.

• Caris' Precision Oncology Alliance Welcomes Loma Linda University Cancer Center

  5/5/2022

  Caris Life Sciences® announced today that Loma Linda University Cancer Center (LLU Cancer Center) has joined Caris' Precision Oncology Alliance™ (POA).

• Caris Life Sciences Announces Continued Growth and Investment with Opening of New Liquid Biopsy Laboratory Facility

  4/25/2022

  Caris Life Sciences® announced the opening of a new liquid biopsy laboratory in Phoenix, Arizona, which will further expand the company's molecular profiling capabilities, which include tumor profiling and innovative blood-based cancer diagnostics.

• Caris' Precision Oncology Alliance Welcomes The University of Kentucky Markey Cancer Center

  4/14/2022

  Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, announced that The University of Kentucky Markey Cancer Center has joined Caris' Precision Oncology Alliance™.

• New Research from the Caris Precision Oncology Alliance Finds Prognostic and Predictive Drug-Induced Gene Signatures for Colorectal Cancer Patients

  4/8/2022

  Caris Life Sciences®(Caris), to present findings that provide a deeper understanding that tumor expression of genes related to extent of drug exposure, stratified by p53 status, is associated with clinical outcomes on the common chemotherapeutic regimens used to treat metastatic colorectal cancer (CRC).

• Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies

  3/29/2022

  Zentalis Pharmaceuticals, Inc. today announced a strategic collaboration with Caris Life Sciences, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare.

• Caris' Precision Oncology Alliance Welcomes Tampa General Hospital Cancer Institute

  3/1/2022

  Caris Life Sciences ® announced today that Tampa General Hospital Cancer Institute (TGH Cancer Institute) has joined Caris' Precision Oncology Alliance™ (POA).

• National Cancer Center Japan Joins Caris' Precision Oncology Alliance

  2/10/2022

  Caris and NCC Japan expand their partnership to drive new evidence generation across various tumor groups, while tracking longitudinal outcomes.

• Caris' Precision Oncology Alliance Welcomes The Ohio State University Comprehensive Cancer Center

  2/8/2022

  Caris Life Sciences announced today that the The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has joined Caris' Precision Oncology Alliance™ (POA).

• 

  BioSpace Movers & Shakers, Jan. 14

  1/14/2022

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• HotSpot Therapeutics and Caris Life Sciences Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets

  1/10/2022

  HotSpot Therapeutics, Inc. and Caris Life Sciences® announced a strategic partnership to advance precision medicine approaches for HotSpot's emerging product portfolio.

• Caris Life Sciences and HotSpot Therapeutics Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets

  1/10/2022

  Caris Life Sciences® and HotSpot Therapeutics, Inc. announced a strategic partnership to advance precision medicine approaches for HotSpot's emerging product portfolio.

• Caris Life Sciences Announces Appointment of Rob Clark as Chief Communications Officer

  1/7/2022

  Caris Life Sciences announced today the appointment of Rob Clark  as Senior Vice President and Chief Communications Officer.

• Caris Life Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  Caris Life Sciences announced today that the Company will present at the 40th Annual J.P. Morgan Healthcare Conference, which is being held virtually on January 10-13, 2022 .

• Caris Life Sciences Announces Appointment of Lloyd B. Minor to Board of Directors

  11/19/2021

  Caris Life Sciences announced today the appointment of Lloyd B. Minor , M.D. to the Caris Board of Directors, effective immediately.

• Caris Precision Oncology Alliance Announces the Addition of Columbia University Irving Medical Center to Its Collaborative Network of Precision Medicine Experts

  11/18/2021

  Caris Life Sciences®  announced today that the Herbert Irving Comprehensive Cancer Center (HICCC) has joined Caris' Precision Oncology Alliance™ (POA).

• Caris' Precision Oncology Alliance Welcomes The Georgia Cancer Center at Augusta University

  11/11/2021

  Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that the Georgia Cancer Center at Augusta University has joined Caris' Precision Oncology Alliance™.

• Caris Precision Oncology Alliance Partners with the National Cancer Institute, Part of the National Institutes of Health, to Expand Collaborative Clinical Research Efforts

  10/29/2021

  Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, announced that the Caris Precision Oncology Alliance™ and NCI's Center for Cancer Research will collaborate on precision medicine research initiatives.

• Caris Life Sciences and Ono Pharmaceutical Announce Strategic Collaboration Leveraging Caris' Novel, Blood-Based cNAS Molecular Profiling Assay Across Several Ono Clinical Studies

  10/14/2021

  Caris Life Sciences® and Ono Pharmaceutical Co., Ltd. announced a strategic collaboration to leverage Caris' best-in-class molecular profiling, including its novel, liquid biopsy circulating nucleic acids sequencing assay, across several studies beginning later this year.

• Andreas Tsukada Joins Caris Life Sciences as President of Japanese Operations and Head of International

  10/12/2021

  Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, announced that Andreas S. Tsukada has joined the Company as Senior Vice President, President of Japanese Operations and Head of International.